Baxter to Present at the UBS Global Life Sciences Conference

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 8:00 a.m. (ET) or 7:00 a.m. (CT).

The live webcast of Baxter's presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through October 22, 2010.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Investor Relations:
Mary Kay Ladone, +1-847-948-3371
or
Media:
Deborah Spak, +1-847-948-2349

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Other Science  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.